Overview

Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca